Nautilus Biotechnology posts first revenue, Q2 net loss narrows

Nautilus Biotechnology

28/07/2026 13:10

Overview
US proteomics platform developer reported first revenue in Q2 2026, driven by grant and service sales
Operating expenses fell 7% yr/yr, net loss narrowed slightly from prior year
Company shifted resources to accelerate proteoform applications, with no incremental spend

Outlook
Nautilus expects Voyager platform pre-orders in early 2027, instrument shipments in mid 2027
Company anticipates general availability of Tau and AKT1 consumable kits in mid 2027
Nautilus plans to report commercial timeline for Broadscale Assay at a future date

Result Drivers
FIRST REVENUE SOURCES - Q2 revenue driven by grant from Michael J. Fox Foundation and initial service sales under Iterative Mapping Early Access Program
RESOURCE REALLOCATION - Co shifted resources to accelerate proteoform applications in response to customer demand, without increasing overall spending
LOWER OPERATING COSTS - Operating expenses fell due to lower salaries, stock-based compensation, and facilities costs

Company press release: ID:nGNX23sBnH

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.11
 
Q2 Net Loss
 
$14.47 mln
 
Q2 Operating Expenses
 
$15.94 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $4.00, about 141% above its July 27 closing price of $1.66

Reuters Recommended Reads
July 28 - Repligen Q2 revenue beats estimates on higher orders; raises outlook
July 28 - Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales
July 27 - UK's Science Group preliminary H1 core revenue falls; expects buyback to exceed £20 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)